IL-17A & Anti-TNF Biologic Spinal Remission Therapy
Comprehensive axial spondyloarthritis management combining anti-TNF (Infliximab / Etanercept) and anti-IL-17A (Secukinumab) biologics, targeted hydrotherapy, and posture rehabilitation preventing spinal bamboo ankylosis.
Ankylosing spondylitis treatment
Clinical Overview & Disease Information
Comprehensive axial spondyloarthritis management combining anti-TNF (Infliximab / Etanercept) and anti-IL-17A (Secukinumab) biologics, targeted hydrotherapy, and posture rehabilitation preventing spinal bamboo ankylosis.
Signs & Symptoms
- • Inflammatory low back pain lasting > 3 months (worse in morning/rest, improves with exercise)
- • Gluteal alternating buttock pain and morning spine stiffness
- • Progressive loss of spinal flexibility (Schober test < 4cm)
- • Kyphotic posture (stooped spine) and painful heel enthesitis (Achilles tendonitis)
- • Acute anterior uveitis (painful red eye with photophobia)
- • Spinal fracture post minor trauma due to rigid "bamboo spine" ankylosis
Causes & Risk Factors
Primary Causes & Etiology
- HLA-B27 genetic allele strongly associated with gut-joint immune dysregulation
- Enthesitis and subchondral bone marrow edema in sacroiliac joints
- Pro-inflammatory Interleukin-17 (IL-17A) & TNF-alpha drive
Who is at Higher Risk?
- Young adults (aged 18-35) with chronic inflammatory back pain and HLA-B27 positivity
Diagnostic Evaluation & Testing
| Diagnostic Test | Clinical Purpose / What It Shows |
|---|---|
| Whole Spine & Sacroiliac Joint 3.0T MRI (T2-FS / STIR Sequences) | Detects active subchondral bone marrow edema (active sacroiliitis) years before X-ray changes |
| HLA-B27 Genetic Allele Polymerase Chain Reaction (PCR) | Confirms genetic predisposition in axial spondyloarthritis |
Comprehensive Treatment Options
Targeted Anti-IL-17A Biologic (Secukinumab) / Anti-TNF (Etanercept) SC Therapy
Monthly subcutaneous Secukinumab or Etanercept injections halting enthesitis, bone marrow edema, and new syndesmophyte formation.
Pedicle Subtraction Osteotomy (PSO) for Severe Kyphotic Deformity
Complex spinal osteotomy correcting fixed chin-on-chest deformity.
Advanced Medical Technologies Available in Partner Hospitals
Possible Complications If Untreated
Recovery Timeline, Diet & Lifestyle Care
Recovery Timeline
| Procedure / Stage | Expected Recovery Duration |
|---|---|
| Subcutaneous Insemination / Injection | 30 minutes |
| Resolution of Morning Back Stiffness | 3 to 7 days |
| Full BASDAI Remission & Active Mobility | 2 to 3 months |
Recommended Post-Treatment Diet
- Anti-inflammatory diet (high in fish oils, turmeric, greens)
- Low starch diet option
Essential Lifestyle Changes
- Perform daily morning spinal extension exercises and posture stretches
- Sleep on a firm mattress with a single thin flat pillow
- 100% smoking cessation
Prevention & Long-Term Health
Frequently Asked Questions
Can Secukinumab stop my spine from fusing in Ankylosing Spondylitis?
Yes, Secukinumab (anti-IL-17A) targets the exact pathway responsible for bone inflammation and new bone formation, preventing progressive spinal fusion.
Top Recommended Specialists Available
Dr. Namita Jaggi
Chairperson- Lab Services and Infection Control & Chief- Education & Research
View Doctor Profile →
Dr. Namita Jaggi
Chairperson - Lab Services & Infection Control; Chief - Education & Research
View Doctor Profile →
Global Cost Comparison Matrix
| Procedure | USA (Avg) | India (ISG) | Turkey (Avg) | Thailand (Avg) |
|---|---|---|---|---|
| Ankylosing spondylitis treatment | $22,000 | $2,500 | $6,800 | $7,500 |
Request Free Clinical Opinion & Cost Estimate
Upload your diagnostic reports or medical summary for a free review by leading specialists within 24-48 hours.
Get Free Treatment EstimateCommonly Prescribed Medications
- Secukinumab (Cosentyx) 150mg SC
- Indomethacin SR 75mg
- Sulfasalazine 2g daily
International Patient Guide
- Passport & Visa
- Sacroiliac Joint MRI CDs & HLA-B27 PCR Report